What is the recommended dose of erdafitinib?

The recommended dose design of Erdafitinib (Erdafitinib) for the treatment of urothelial cancer (bladder cancer) takes full consideration of individual differences and pharmacokinetic properties, and adopts an adjustable starting dose regimen. Generally speaking, the recommended starting dose for adult patients is 8 mg once daily, taken orally continuously. After 14 days of uninterrupted use, the doctor can decide whether to increase the dose to 9 mg daily based on the patient's blood phosphorus concentration and overall tolerance. Serum phosphorus levels are a key indicator for monitoring the response to this drug treatment, because erdafitinib interferes with phosphorus metabolism by inhibiting the FGFR signaling pathway, leading to an increase in serum phosphorus. Moderately elevated blood phosphorus concentrations are thought to be positively correlated with treatment effectiveness, so in the early stages of treatment, doctors will recommend patients have regular blood tests to monitor and guide dose adjustments.

It is worth noting that although9 mg is considered the upper limit of the effective dose, in patients with specific side effects, doctors can also reduce the dose to 6 mg or even lower based on individual tolerance to ensure safety and the possibility of continued treatment. If adverse eye reactions occur during medication, such as blurred vision or dryness, the medication may need to be temporarily discontinued or the dosage reduced. For patients with liver and kidney dysfunction, there is currently no sufficient evidence to guide dosage adjustment, so special caution is required when using the drug, and it is best to proceed under the guidance of a professional doctor.

In terms of taking method, erdafitinib is recommended to be taken on an empty stomach or with food, but it should be taken at the same time every day to maintain a stable blood concentration. If a dose is missed, it is not recommended to take it twice in a short period of time. You should skip the dose and continue as planned. In general, the dose management of erdafitinib emphasizes the principle of "individualization". The key to successful treatment is that doctors can flexibly adjust the dose according to the patient's genetic characteristics, metabolic capacity and toxic reactions, thereby balancing efficacy and safety, reflecting the practical concept of modern precision medicine.

Reference materials：https://www.balversa.com/